John G Ullman & Associates Inc. Decreases Stock Holdings in Jazz Pharmaceuticals plc (NASDAQ:JAZZ)

John G Ullman & Associates Inc. trimmed its holdings in shares of Jazz Pharmaceuticals plc (NASDAQ:JAZZ) by 11.9% in the fourth quarter, HoldingsChannel.com reports. The fund owned 39,750 shares of the specialty pharmaceutical company’s stock after selling 5,344 shares during the period. John G Ullman & Associates Inc.’s holdings in Jazz Pharmaceuticals were worth $4,895,000 as of its most recent filing with the Securities and Exchange Commission.

Other institutional investors and hedge funds also recently modified their holdings of the company. IFP Advisors Inc purchased a new stake in shares of Jazz Pharmaceuticals during the fourth quarter valued at approximately $25,000. UMB Bank n.a. increased its position in Jazz Pharmaceuticals by 70.9% in the fourth quarter. UMB Bank n.a. now owns 311 shares of the specialty pharmaceutical company’s stock worth $38,000 after buying an additional 129 shares during the last quarter. Itau Unibanco Holding S.A. increased its position in Jazz Pharmaceuticals by 63.2% in the third quarter. Itau Unibanco Holding S.A. now owns 444 shares of the specialty pharmaceutical company’s stock worth $49,000 after buying an additional 172 shares during the last quarter. GAMMA Investing LLC increased its position in Jazz Pharmaceuticals by 49.8% in the fourth quarter. GAMMA Investing LLC now owns 620 shares of the specialty pharmaceutical company’s stock worth $76,000 after buying an additional 206 shares during the last quarter. Finally, Venturi Wealth Management LLC increased its position in Jazz Pharmaceuticals by 577.0% in the third quarter. Venturi Wealth Management LLC now owns 826 shares of the specialty pharmaceutical company’s stock worth $92,000 after buying an additional 704 shares during the last quarter. 89.14% of the stock is owned by hedge funds and other institutional investors.

Insider Activity

In other news, CEO Bruce C. Cozadd sold 1,500 shares of the business’s stock in a transaction dated Monday, February 3rd. The stock was sold at an average price of $122.31, for a total value of $183,465.00. Following the completion of the sale, the chief executive officer now owns 439,744 shares of the company’s stock, valued at approximately $53,785,088.64. The trade was a 0.34 % decrease in their position. The transaction was disclosed in a legal filing with the SEC, which is accessible through this link. In the last quarter, insiders sold 5,053 shares of company stock valued at $617,442. Insiders own 4.20% of the company’s stock.

Wall Street Analyst Weigh In

JAZZ has been the subject of a number of recent research reports. Cantor Fitzgerald downgraded Jazz Pharmaceuticals from an “overweight” rating to a “neutral” rating and raised their target price for the stock from $140.00 to $150.00 in a research report on Wednesday. Wells Fargo & Company raised Jazz Pharmaceuticals from an “equal weight” rating to an “overweight” rating and raised their target price for the stock from $130.00 to $170.00 in a research report on Thursday, February 13th. Robert W. Baird raised their target price on Jazz Pharmaceuticals from $154.00 to $162.00 and gave the stock an “outperform” rating in a research report on Monday, November 18th. TD Cowen decreased their target price on Jazz Pharmaceuticals from $200.00 to $195.00 and set a “buy” rating for the company in a research report on Thursday, November 7th. Finally, JPMorgan Chase & Co. lifted their price target on Jazz Pharmaceuticals from $200.00 to $209.00 and gave the company an “overweight” rating in a research report on Wednesday. Two analysts have rated the stock with a hold rating, thirteen have issued a buy rating and one has issued a strong buy rating to the company. According to MarketBeat, the company currently has an average rating of “Moderate Buy” and a consensus target price of $182.47.

Jazz Pharmaceuticals Trading Up 0.2 %

NASDAQ JAZZ opened at $143.53 on Friday. Jazz Pharmaceuticals plc has a 1-year low of $99.06 and a 1-year high of $148.06. The company has a current ratio of 4.26, a quick ratio of 3.74 and a debt-to-equity ratio of 1.46. The stock has a 50-day moving average of $126.69 and a 200-day moving average of $119.04. The firm has a market cap of $8.68 billion, a PE ratio of 20.22, a price-to-earnings-growth ratio of 1.04 and a beta of 0.56.

Jazz Pharmaceuticals Company Profile

Jazz Pharmaceuticals plc identifies, develops, and commercializes pharmaceutical products for unmet medical needs in the United States, Europe, and internationally. The company offers Xywav for cataplexy or excessive daytime sleepiness (EDS) with narcolepsy and idiopathic hypersomnia; Xyrem to treat cataplexy or EDS with narcolepsy; Epidiolex for seizures associated with Lennox-Gastaut and Dravet syndromes, or tuberous sclerosis complex; Zepzelca to treat metastatic small cell lung cancer, or with disease progression on or after platinum-based chemotherapy; Rylaze for acute lymphoblastic leukemia or lymphoblastic lymphoma; Enrylaze to treat acute lymphoblastic leukemia and lymphoblastic lymphoma; Defitelio to treat severe hepatic veno-occlusive disease; and Vyxeos for newly-diagnosed therapy-related acute myeloid leukemia.